Related Experiment Video
Updated: Jul 13, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Hypoglycemia-associated autonomic failure in diabetes
1Division of Endocrinology, Diabetes and Metabolism, General Clinical Research Center , Washington University School of Medicine, St. Louis, Missouri 63110, USA. pcryer@im.wustl.edu
American Journal of Physiology. Endocrinology and Metabolism
|November 10, 2001
Summary
Hypoglycemia-associated autonomic failure (HAAF) in diabetes leads to recurrent low blood sugar. Avoiding hypoglycemia for 2-3 weeks can reverse this dangerous cycle and improve glucose control.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Diabetes Management
Background:
- Hypoglycemia is a major limitation in diabetes glycemic control.
- Hypoglycemia-associated autonomic failure (HAAF) describes impaired counterregulation and awareness after prior hypoglycemia.
- HAAF creates a cycle of recurrent hypoglycemia in individuals with diabetes.
Purpose of the Study:
- To explain the pathophysiology of hypoglycemia-associated autonomic failure (HAAF).
- To investigate the impact of antecedent hypoglycemia on glucose counterregulation and awareness.
- To provide a framework for reducing iatrogenic hypoglycemia in diabetes.
Main Methods:
- The study discusses the concept of HAAF based on existing research and clinical observations.
- It highlights findings related to the reversal of HAAF symptoms with hypoglycemia avoidance.
- The framework considers clinical risk factors and indexes of compromised glucose counterregulation.
Main Results:
- Recurrent hypoglycemia leads to defective glucose counterregulation and unawareness.
- Avoiding hypoglycemia for 2-3 weeks can reverse hypoglycemia unawareness.
- This avoidance period also improves the epinephrine response in defective glucose counterregulation.
Conclusions:
- HAAF is a significant factor in recurrent hypoglycemia in diabetes.
- Reversing HAAF through hypoglycemia avoidance is achievable and improves glycemic control.
- Understanding HAAF pathophysiology is crucial for eliminating iatrogenic hypoglycemia in diabetes management.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:22Complications of Diabetes Mellitus
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia due to insulin deficiency, resistance, or both. Prolonged hyperglycemia disrupts metabolic homeostasis and leads to acute and chronic complications.Acute ComplicationsAcute complications result from sudden metabolic imbalance.Diabetic ketoacidosis (DKA) mainly appears in type 1 diabetes but may also develop in type 2 diabetes, particularly under extreme stress. It arises from severe insulin deficiency,...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:22Diabetic Neuropathy
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...